Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective study-Reference-Cited by-同舟云学术

Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective study

Published:2020-12-12 Issue:4 Volume:28 Page:369-375
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int. J. Urol.

Author:

Hatakeyama Shingo¹,Naito Sei²,Numakura Kazuyuki³,Kato Renpei⁴,Koguchi Tomoyuki⁵,Kojima Takahiro⁶,Kawasaki Yoshihide⁷,Kandori Shuya⁶,Kawamura Sadafumi⁸,Tsushima Eiki⁹,Nishiyama Hiroyuki⁶,Ito Akihiro⁷,Kojima Yoshiyuki⁵,Habuchi Tomonori³,Obara Wataru⁴,Tsuchiya Norihiko²,Ohyama Chikara¹

Affiliation:

1. Department of Urology and Advanced Blood Purification Therapy Hirosaki University Graduate of Medicine Hirosaki AomoriJapan

2. Department of Urology Yamagata University School of Medicine Yamagata YamagataJapan

3. Department of Urology Akita University School of Medicine Akita AkitaJapan

4. Department of Urology Iwate Medical University School of Medicine Morioka IwateJapan

5. Department of Urology Fukushima Medical University School of Medicine Fukushima FukushimaJapan

6. Department of Urology University of Tsukuba Graduate School of Medicine Tsukuba IbarakiJapan

7. Department of Urology Tohoku University School of Medicine Sendai MiyagiJapan

8. Department of Urology Miyagi Cancer Center Natori MiyagiJapan

9. Department of Physical Therapy Hirosaki University Graduate School of Health Sciences Hirosaki Aomori Japan

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.14466

Reference30 articles.

1. Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer

2. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

3. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

4. C‐reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinoma

5. New prognostic model for synchronous metastatic renal cell carcinoma

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the modern era;Translational Andrology and Urology;2024-05

2. Comparison of upfront versus deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma receiving systemic therapy: A systematic review and meta-analysis;International Journal of Surgery;2023-07-17

3. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era: a systematic review and meta-analysis;International Journal of Surgery;2023-03-28

4. Deferred cytoreductive nephrectomy in the management of metastatic renal cell carcinoma: A systematic review and meta-analysis;Urologic Oncology: Seminars and Original Investigations;2023-03

5. Editorial Comment to Surgical and focal treatment for metastatic renal cell carcinoma: A literature review;International Journal of Urology;2022-03-26